ReviewMicroorganisms2024
The Daunomycin: Biosynthesis, Actions, and the Search for New Solutions to Enhance Production.
Review in Microorganisms, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Increased MYB alternative promoter usage induces daunorubicin resistance in human leukemia cells via ABCA2 upregulation.Molecular biology reports · 2026Article
- The effect of platinum nanoparticles on the physicochemical properties of daunorubicin.RSC advances · 2025Article
- Characterization of natural therapeutic compounds producing novel bacterial strains isolated from Hyderabad, India.Scientific reports · 2025Article
- Genome mining identifies a diversity of natural product biosynthetic capacity in human respiratorymSphere · 2025Article
- Autonomous Defense Based on Biogenic Nanoparticle Formation in Daunomycin-ProducingMicroorganisms · 2025Article
- Coordinated regulation of propionyl-CoA carboxylase subunits drives precursor flux optimization in spinosad production.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Daunorubicin (DNR) is an anthracycline antibiotic originating from soil-dwelling actinobacteria extensively used to treat malignant tumors. Over the decades, extensive attempts were made to enhance the production of anthracyclines by introducing genetic modifications and mutations in combination with media optimization, but the target production levels remain comparatively low. Developing an appropriate culture medium to maximize the yield of DNR and preventing autotoxicity for the producing organism remains a challenge. Our prospective review sheds light on a method involving perturbation that enhances the precursors to regulate the type II PKS pathway, enhancing cells' capacity to increase secondary metabolite production. The suggested method also entails the preparation of culture media for the cultivation of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.